Artiva Biotherapeutics
ARTV
57 hedge funds and large institutions have $213M invested in Artiva Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 6 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 6
16% more funds holding
Funds holding: 49 → 57 (+8)
1.78% more ownership
Funds ownership: 85.34% → 87.12% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
33% less capital invested
Capital invested by funds: $319M → $213M (-$106M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.51M |
| 2 |
State Street
Boston,
Massachusetts
|
+$940K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$345K |
| 4 |
JP Morgan Chase
New York
|
+$323K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$311K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$84.1K |
| 2 |
SO
STRS Ohio
Columbus,
Ohio
|
-$40.2K |
| 3 |
Morgan Stanley
New York
|
-$32K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$23.4K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$11.5K |
ARTV Hedge Fund Activity: Q4 2024 in Review
57 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q4 2024, worth a combined $213M — down 33% from $319M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ARTV positions and 1 closed out — a net gain of 8 holders — while 18 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $2.51M. The largest seller was Bank of America, cutting an estimated $84.1K.
- 57 institutional investors held Artiva Biotherapeutics (ARTV) as of Q4 2024, up from 49 in Q3 2024.
- Funds reported $213M of Artiva Biotherapeutics stock for Q4 2024, down 33% quarter-over-quarter.
- 9 funds opened new Artiva Biotherapeutics positions in Q4 2024 and 1 closed out, a net change of +8 holders.
- The largest Artiva Biotherapeutics buyer in Q4 2024 was BlackRock, an estimated $2.51M added.
- The largest Artiva Biotherapeutics seller in Q4 2024 was Bank of America, an estimated $84.1K sold.
Based on aggregated 13F filings for Q4 2024.